Over 3 weeks since the Halt , only 1/2 of Ann, SP heading further South, SI ??????, page-154

While there is commentary on MESO/NASDAQ/Mesoblast etc thought i'd remind you that.... and yes these "experts" are not to be taken at their word but...

Mesoblast limited (NASDAQ:MESO) Receives Consensus Recommendation of “Hold” from Analysts

June 29th, 2016 - 0 comments - Filed Under - by Kyle Jackso

Mesoblast limited (NASDAQ:MESO) has received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the stock. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.50.
MESO has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Mesoblast limited from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Friday, March 25th. JPMorgan Chase & Co. cut shares of Mesoblast limited from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $9.00 to $10.00 in a research note on Monday, March 7th. Credit Suisse cut shares of Mesoblast limited from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $10.00 to $5.00 in a research note on Tuesday, June 14th. Finally, Maxim Group reiterated a “buy” rating and issued a $14.00 price objective (down previously from $18.00) on shares of Mesoblast limited in a research note on Tuesday, May 10th.
Mesoblast limited (NASDAQ:MESO) opened at 3.89 on Friday. Mesoblast limited has a one year low of $3.50 and a one year high of $15.56. The company has a 50-day moving average of $6.03 and a 200 day moving average of $6.97. The firm’s market capitalization is $293.40 million.
Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.